ARNA Related Insiders' Blog
-
Obesity Gets Some Respect (ARNA) (VVUS) (OREX)
-
American Medical Association Calls Obesity A Disease (ARNA) (VVUS)
-
VIVUS (VVUS) Qsymia Prescriptions Fall Ahead of Belviq Launch (ARNA)
-
Arena (ARNA) Slumps as Consumer Reports Says to 'Skip' Belviq
-
VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
-
Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
-
VIVUS, Inc. (VVUS) Ticks Higher as Arena (ARNA) Pulls BELVIQ MAA in Europe
-
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
-
Risks vs. Benefits of Bariatric Surgery Might Put Obesity Pills in Lime Light (ARNA) (VVUS) (OREX)
-
Obesity Pill Makers in Focus as EMA CHMP Denies Belviq MAA (ARNA) (VVUS) (OREX)
-
Arena (ARNA) Chugs Higher on Volume; Will Present at JP Morgan Conf. Tomorrow
-
Orexigen (OREX) Pops Higher as Contrave May Get Speedier Approval (VVUS) (ARNA)
-
Arena (ARNA) Partner Eisai May Also Have Promising Weight-Loss Pill in the Works
-
FDA Might Allow for Faster Approval of Obesity Drugs (VVUS) (ARNA) (OREX)
-
Arena (ARNA) Higher as Large PBM Joins Obesity Pill Distribution Network (VVUS)
-
VIVUS (VVUS) Lower Heading into Obesity 2012 Event; Will Present New Qsymia Data
-
Arena (ARNA) Higher as VIVUS (VVUS) Downgrade is Company-Specific, Not Industry Issue
-
Arena Pharma (ARNA) Pops on More Positive Chatter
-
Are Obesity Pills Hammering the Nail in Weight Watchers' (WTW) Coffin? Maybe Not...
-
Biggest Gainers in FY12 To-Date Getting Smacked This Week (ARNA) (VVUS) (LCC)
-
Is the Fun Over for Orexigen (OREX)? (VVUS) (ARNA)
-
VIVUS (VVUS), Orexigen (OREX) Higher Ahead of PDUFA; Arena (ARNA) Lags
-
VIVUS (VVUS) In the Spotlight Ahead of Likely FDA Obesity Drug Approval
-
Prospects for Arena's (ARNA) Belviq Are WAY Overblown - Cramer
-
Arena Pharma (ARNA) Dips; Enrollment Accelerated for Orexigen's (OREX) Contrave Trial
-
Arena Pharma (ARNA) Higher as M&A Chatter Heats Up
-
Chocolate Toothpaste, Another Promising Sign for Arena's (ARNA) Fat Pill
-
Arena Pharma (ARNA) Volatility Up; Shares Trade Higher into VIVUS (VVUS) PDUFA for Qnexa
-
Orexigen (OREX) Higher Again, Shares Now Up ~90% in June Following Arena (ARNA), Analyst Upgrade
-
Orexigen (OREX) Pops Higher on Analyst Upgrade; Volatility Up
-
Arena Pharmaceuticals (ARNA) Dominating on Twitter
-
Arena's (ARNA) Lorcaserin Becomes First Weight-Loss Drug Approved in 13 Years
-
Arena (ARNA) Rivals Mixed Ahead of PDUFA; Volatility Elevated (OREX) (VVUS)
-
Arena (ARNA) Snubs Downgrade, Now Higher on the Session
-
Another Bear Roars at Arena (ARNA); Says Numbers, Potential Overblown
-
Arena-Mania (ARNA) Takes Center Stage and Everyone Has an Opinion
-
Arena Pharmaceuticals (ARNA) Shares Well into Red Territory Early
-
Early Arena Pharma (ARNA) Volume Exceeds 1M Mark; Stock Continues Higher
-
Think Arena (ARNA) Has Topped Out? Better Keep Thinking...
-
Arena Pharma (ARNA) Momentum Continues into PDUFA for Lorcaserin
-
Arena Pharma (ARNA) Continues Chugging After Brief Pause
-
Arena Pharma (ARNA) Sees Early Pressure Following Recent Buying Frenzy
-
Arena Pharma (ARNA) Shares Now Up ~130% Since Positive FDA Panel Vote on Lorcaserin
-
Orexigen (OREX) Catches Bids as Arena (ARNA) Continues Higher
-
Orexigen Therapeutics (OREX) Pops on Positive Arena (ARNA) Comments
-
With Arena Pharmaceuticals (ARNA) Halted Ahead of AdCom, There Will Be Other Ways to Play...
-
Exercise or Pills? Vivus (VVUS) Investors are Banking on Pills...
-
Arena Pharma (ARNA) About 5% Lower; to Raise ~$33M in Private Offering
-
MRK Looking At Acquisitions to Boost Their Drug Business
Back to ARNA Stock Lookup
